Stockscreener 앱 받기
3.145
2.02%
-0.065
시간 외 거래:
3.25
0.105
+3.34%
전일 마감가:
$3.21
열려 있는:
$3.17
하루 거래량:
38,603
Relative Volume:
0.72
시가총액:
$33.92M
수익:
-
순이익/손실:
$-19.09M
주가수익비율:
-2.3801
EPS:
-1.3214
순현금흐름:
$-17.24M
1주 성능:
-8.71%
1개월 성능:
+6.97%
6개월 성능:
-29.17%
1년 성능:
-18.94%
1일 변동 폭
$3.10
$3.41
1주일 범위
$3.10
$3.5998
52주 변동 폭
$2.79
$11.99
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
LTRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.145 | 33.92M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance
15 AI News Updates That Broke The Internet - Insider Monkey
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com
LP-184 gains FDA fast track for triple negative breast cancer - Investing.com
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune
Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace
Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com
Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan
32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.
III: TechBio News Day 👾 - substack.com
LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance
Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace
Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - Yahoo Finance
Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace
FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com
After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph
11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Lantern Pharma secures three new FDA rare disease tags - Investing.com
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace
Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch
Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lantern Pharma Inc 주식 (LTRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fletcher Aaron G.L. | 10% Owner |
May 23 '24 |
Sale |
6.25 |
10,000 |
62,500 |
59,326 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Fletcher Aaron G.L. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Kreis Leslie W. | 10% Owner |
Feb 28 '24 |
Sale |
4.85 |
74,297 |
360,340 |
62,088 |
| Kreis Leslie W. | 10% Owner |
Feb 27 '24 |
Sale |
4.40 |
50,000 |
220,000 |
68,997 |
| Kreis Leslie W. | 10% Owner |
Feb 29 '24 |
Sale |
4.87 |
19,703 |
95,954 |
60,256 |
| Fletcher Aaron G.L. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
| Kreis Leslie W. | 10% Owner |
Jan 17 '24 |
Sale |
4.20 |
58,889 |
247,334 |
73,646 |
2.88%
2.65%
자본화:
|
볼륨(24시간):